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Abstract
Unlike its application for atherosclerotic
plaque analysis, Raman microspectroscopy
was sporadically used to check the sole nature
of bioapatite deposits in stenotic aortic
valves, neglecting the involvement of accu-
mulated lipids/lipoproteins in the calcific
process. Here, Raman microspectroscopy was
employed for examination of stenotic aortic
valve leaflets to add information on nature
and distribution of accumulated lipids and
their correlation with mineralization in the
light of its potential precocious diagnostic
use. Cryosections from surgically explanted
stenotic aortic valves (n=4) were studied
matching Raman maps against specific histo-
logical patterns. Raman maps revealed the
presence of phospholipids/triglycerides and
cholesterol, which showed spatial overlapping
with one another and Raman-identified
hydroxyapatite. Moreover, the Raman pat-
terns correlated with those displayed by both
von-Kossa-calcium- and Nile-blue-stained
serial cryosections. Raman analysis also pro-
vided the first identification of carotenoids,
which co-localized with the identified lipid
moieties. Additional fit concerned the distri-
bution of collagen and elastin. The good cor-
relation of Raman maps with high-affinity
staining patterns proved that Raman
microspectroscopy is a reliable tool in evalu-
ating calcification degree, alteration/displace-
ment of extracellular matrix components, and
accumulation rate of different lipid forms in
calcified heart valves. In addition, the novel
identification of carotenoids supports the
concept that valve stenosis is an atherosclero-
sis-like valve lesion, consistently with their
previous Raman microspectroscopical identi-
fication inside atherosclerotic plaques.
Introduction
Calcific aortic valve stenosis (CAVS) still
represents the leading indication for valve
replacement in aging Western populations.
CAVS shares clinical and histopathological
features with atherosclerosis,1-3 leading to the
increasingly accepted concept that these two
diseases may represent the same disorder
occurring in different anatomical sites.4,5
Notably, in both stenotic valves2,3 and athero-
sclerotic plaques6,7 calcium salt precipitation
on accumulated cholesterol has been reported
as a distinctive event. What cause-and-effect
relationship may exist between the presence
of this neutral lipid and calcium salt nucle-
ation is yet to be exhaustively elucidated, in
contrast with the more easily conceivable
involvement of negatively charged phospho-
lipids (PLs) in pathological biomineralization
processes. Consistently, cell-membrane-
derived acidic PLs have been identified as
major calcium nucleator in both CAVS8,9 and
atherosclerosis.10 In addition, using the pro-
calcific subdermal model, PL involvement has
been ultrastructurally shown in the context of
a peculiar degenerative process affecting aor-
tic valve interstitial cells (AVICs), in which
the crucial event was a progressive colliqua-
tion of all cell membranes, culminating with
the generation of an acidic-PL-rich material
outlining dying cells or their remnants and
acting as a major hydroxyapatite (HA) nucle-
ator.11-14 Similar cell degeneration has also
been shown to concern AVICs in in vitro mod-
els simulating dystrophic15 and metastatic16
calcification. Raman microspectroscopy is an
analytical technique measuring the charac-
teristic molecular vibrations of various chem-
ical groups after irradiation with a laser
beam.17 Using this technique, HA, cholesterol,
and carotenoids have been identified within
atherosclerotic plaques,18-20 whereas identifi-
cation of HA solely has been reported for
stenotic aortic valves.21,22
The present investigation was aimed to
better characterize tissue alterations and par-
allel accumulation of HA and different lipids
in CAVS-affected aortic valve leaflets as well
as evaluate whether Raman microspec-
troscopy can be concerned as a potential diag-
nostic tool, by matching the achieved ex vivo
Raman maps against specific histological pat-
terns. Raman maps of HA, PLs/triglycerides
(PLs/TGs), cholesterol, and carotenoids
exhibited spatial overlapping with one anoth-
er and histological patterns, besides provid-
ing the novel identification of carotenoids in
these calcific valves.
Materials and MethodsSampling and initial processing
Native, tricuspid aortic valves were surgical-
ly explanted from patients (n=4; mean age
78±8 years) subjected to cardiac valve replace-
ment at the Cardiothoracic Surgery Unit of the
University Hospital of Udine. The present
investigation was approved by the Internal
Review Board (IRB) of the Department of
Experimental and Clinical Medicine so human
studies have been performed in accordance
with the ethical standards laid down in the
1964 Declaration of Helsinki and its later
amendments. Informed consent allowing aor-
tic valve use for experimental purposes was
signed by all patients prior to their inclusion in
the study. All aortic valves were affected by
severe, non-rheumatic stenosis as diagnosed
by pre-operative clinical and echocardiograph-
ic parameters (valve area <1 cm2; middle
transvalvular gradient >65 mmHg). After
explantation, aortic valves were immersed in
sterile 0.9% NaCl solution and their leaflets
were excised and subdivided into two hemi-
cusps by cutting them along the middle longi-
tudinal axis. For each patient, one hemi-cusp
was cooled by dipping into 2-methylbutane liq-
uid for subsequent Raman and histological
analyses, being the other one formalin-fixed
for routinary hematoxylin&eosin staining.
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Cryosectioning
For each cooled hemi-cusp, three 1.5-mm-
spaced, 15-μm-thick cryosections (n=12) were
longitudinally cut, mounted on CaF2 slides, air-
dried, and stored at -20°C for subsequent
Raman microspectroscopic examination.
Additional serial and para-serial 8-µm-thick
cryosections were mounted on glass slides, air-
dried, and fixed with phosphate-buffered 5%
formaldehyde for subsequent histological
staining, as described below.Raman microspectroscopy
Raman maps were collected in back scatter-
ing geometry using the Renishaw InVia
Raman microscope equipped with a 785 nm
diode laser delivering 170mW of laser power at
the sample. A 785 nm near infrared wave-
length was used to limit tissue autofluores-
cence, which should interfere with Raman
spectrum measurements. The CaF2 slide sup-
porting the tissue sections was mounted on a
ProScan II motorized stage (Prior, Cambridge,
UK) under the microscope. A Leica 50 micro-
scope objective (N.A. 0.85) focused the laser
on the sample. A 1200 L/mm grating yielded a
spectral resolution of 4 cm–1. A thermoelectri-
cally cooled charge coupled device (CCD) cam-
era was used for detection. The spectrograph
was calibrated using the lines of a Ne lamp.
Mapping was achieved collecting spectra with
steps of 12 μm, with 10 sec exposure time for
each spectrum, for a total of 5708 spectra, each
consisting of 1203 data points. Spectra were
obtained in the 600-1800 cm–1 region using the
synchro mode of the instrument software
WiRETM 3.2 (Renishaw), in which the grating
is continuously moved to obtain Raman spec-
tra of extended spectral regions. Data prepro-
cessing and analysis were carried out using
the hyperSpec package (Beleites and Sergo,
hyperSpec: a package to handle hyperspectral
data sets in R; http://hyperspec.r-forge.r-pro-
ject.org/).High-affinity histological stainingvon Kossa staining 
Serial cryosections were treated with 1% sil-
ver nitrate solution for 15 min, with exposure
to direct sunlight, and 5% sodium thiosulfate
reducing solution for 5 min. Cryosections were
then weakly counterstained with hematoxylin
and eosin, dehydrated in graded ethanols,
cleared with xylene, and mounted with Eukitt®
mounting medium.Movat staining 
Para-serial cryosections were stained with
1% alcian blue acidic solution for 40 min, dif-
ferentiated in 0.3% sodium carbonate solution
for 2 h, and then incubated with i) Weigert’s
resorcin-fuchsin solution for 40 min; ii) celes-
tine blue solution for 5 min; iii) Weigert’s iron
hematoxylin for 10 min; and iv) van Gieson
solution for 5 min. Dehydration and mounting
were as described above.Nile blue staining
Para-serial cryosections were stained with
1% Nile blue solution at 60°C for 5 min, differ-
entiated in warm 1% acetic acid solution, and
mounted with glycerol mounting medium.
Discrimination between neutral lipids and
acidic lipids is allowed because the used dye is
a mixture of oxazone (Nile red) and oxazine
sulphate (Nile blue), in that the former is
mainly dissolved by neutral lipids and the lat-
ter by acidic ones. Observation and recording
were made using a Zeiss AxioImager photomi-
croscope.
Results
Figure 1 shows the Raman spectrum calcu-
lated as the average of all intensity-normalized
spectra collected in the map from a representa-
tive CAVS-affected valve leaflet cryosection. All
the bands usually observed in Raman spectra
of biological tissues were detected, such as the
sharp and intense band at 1004 cm–1 assigned
to the phenylalanine ring vibration, the bands
at 1250-1270 cm–1 and 1600-1700 cm–1 assigned
to amide I and III vibrational modes respective-
ly, and the bands at 1400-1500 cm–1 assigned to
-CH2- and -CH3- deformation modes.
Characteristic spectral peaks were also detect-
ed of type B carbonate HA at 959 cm–1, collagen
at 877, 922, and 939 cm–1, elastin at 1103 and
1340 cm–1, PLs/TGs at 719 and 1738 cm–1, cho-
lesterol at 700 and 741 cm–1, and carotenoids at
1159 and 1527 cm–1. The presence of unsatu-
rated lipids was inferred from the small, but
still distinguishable, peak at 1660 cm–1 super-
imposing to the broad amide I protein peak.
Peaks at 1064 and 1128 cm–1 indicated the
presence of saturated fatty acid chains.23 All
spectra collected from the other cryosections
revealed the presence of the same chemical
species, although showing slight changes in
their peak intensities (not shown).
The measured Raman intensities were fur-
ther converted into chemical images displaying
the relative concentrations of the chemical
species identified in the analyzed valve leaflet
cross cryosections side-by-side, so including
all three layers called tunica fibrosa, tunica
spongiosa, and tunica ventricularis, in which
major tissue alterations were detectable in the
fibrosa layer (Figure 2 A-C and G-I). The
expression relative concentrations means that
in each image color scales span minimum to
maximum concentration values of the chemi-
cal species in its own map, so they cannot be
quantitatively compared to each other. The
Raman map of HA (Figure 2A) showed the
highest intensity to coincide exactly with the
brown calcific nodule recognizable on the seri-
al cryosection subjected to von Kossa silver
staining (Figure 2D). Lower HA intensity
resulted for two pseudo-triangle-shaped areas
                             Original Paper
Figure 1. Mean Raman spectrum of the Raman map collected from a representative
CAVS-affected valve leaflet cryosection, calculated over all the 5708 spectra of the map.
Intensity standard deviation, showing the spectral variability, is shown in light grey. For
all spectra, excitation wavelength was at 785 nm, laser power was 170 mW, and acquisi-
tion time was 10 seconds.
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in the fibrosa layer referred to below as T1 and
T2, the former enveloping the calcific nodule
and the latter located above. Additional very
high intensity was exhibited by random one-
pixel-wide spots located in T1. Also these spots
roughly correlated with the punctate silver pre-
cipitates showed by the von-Kossa-stained
cryosection inside the corresponding area. In
contrast, the HA Raman map showed a mutual
exclusion pattern as opposed to those of colla-
gen (Figure 2B) and elastin (Figure 2C), since
the areas showing higher mineral intensity
were superimposable to those of lower intensi-
ty of the two extracellular matrix fibrous com-
ponents. In turn, Raman patterns of the latter
were roughly consistent with their distribution
on histological cryosections, revealing both
fibrous components by eosin on the counter-
stained von-Kossa-reacted cryosection (Figure
2D) as well as collagen in red and elastin in
dark brown on the Movat-stained cryosection
(Figure 2E). Further fitting resulted for the
maps of the three lipid moieties identified,
which were closely superimposable to each
other (Figure 2 G-I). In addition, the areas
showing intermediate intensity of PLs/TGs
(Figure 2G), cholesterol (Figure 2H), and
carotenoids (Figure 2I) correlated with both T1
and T2 areas in the HA map, including the
presence of single or clustered one-pixel-wide
spots with high intensity. Surprisingly, there
was the exception that lipid maps showed min-
imal intensity just in the area exhibiting the
highest intensity in the HA map, i.e. the calcif-
ic nodule, although some intranodular intensi-
ty appeared for PLs/TGs. Raman maps of lipids
were also roughly consistent with the histolog-
ical patterns shown by the cryosection subject-
ed to Nile blue lipid staining (Figure 2F), since
a red-stained triangle-shaped area, indicating
the presence of neutral lipids, corresponded to
T1 on lipid Raman maps and single or clus-
tered blue-stained punctate sites, indicating
the presence of acidic lipids, were scattered
inside this T1-like area correlating with topical
high Raman intensity of PLs/TGs. In contrast, a
T2-like area was not shown by the histological
counterpart. On the other hand, prominent
Nile blue staining was apparent at the calcific
nodule edge, preserved from artifactual
detachment. All Raman maps concerning the
other cryosections were consistent with the
histological counterparts, although they
showed different topographical distributions of
the identified chemical species (not shown).
Discussion
The present investigation showed that good
consistency exists between Raman maps and
specific histological patterns derived from
cryosections of CAVS-affected valve leaflets,
leading to conclude that this vibrational
microspectroscopy represents a reliable tech-
nique to identify unknown chemical species or
validate those revealed by high-affinity histo-
logical procedures. Combining these two
approaches, the identification, typization, and
localization of HA and distinct lipid forms were
the major outcomes. In particular, HA Raman
maps showed the highest mineral intensity to
correspond exactly to calcific nodules on the
histological counterpart. As inferred from the
Raman shift of the ν1PO43– band at 959 cm–1,
the precipitated mineral was type B carbonate
HA,24 as recently reported using the same tech-
nique.21,22 Taking into account that type B car-
bonate HA represents the most abundant form
of bioapatite in young bones,25 the present
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Figure 2. Images obtained from the Raman map showing the total normalized intensity
of A) hydroxyapatite peak (959 cm–1); B) collagen peaks (877, 922, and 939 cm–1); C)
elastin peaks (1103 and 1340 cm–1); G) phospholipid/triglyceride peaks (719 and 1738
cm–1); H) cholesterol peaks (700 and 741 cm–1); I) carotenoid peaks (1159 and 1527
cm–1). Color scale bars refer to arbitrary units of total normalized intensities. Histological
pictures obtained from D) a serial cryosection subjected to von Kossa calcium staining
and para-serial cryosections stained with E) Movat pentachrome method for extracellular
matrix components or F) Nile blue method for neutral and acidic lipids. Two triangle-
shaped regions are outlined (dashed lines in A and D) in which correlating features can
be appreciated; these regions are promptly recognizable in all Raman images (A-C and
G-I) and are referred as T1 and T2 regions in the text. A calcific nodule portion (asterisk)
is displayed in the lower right corner. Histological slide original magnification: 5x.
Abscissa and ordinate values are expressed in µm.
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result might be consistent with heterotopic
ossification taking place in CAVS. However, it
should be emphasized that i) bone-formed ter-
ritories were never histologically encountered
in this investigation; and ii) bone metaplasia
was reported to be associated with dystrophic
calcification in less than 13% of hundreds of
aortic valves and dozens of mitral valves.26,27
Such a specification is needed because valve
calcification is often misconceived as valve
ossification instead of considering this latter
as an alternative, minority pro-calcific event.
Besides showing marked co-localization of
the three moieties identified, Raman maps of
lipids were also found to be consistent with
lipid distribution in the histological counter-
part. Major fitting concerned the good super-
imposability of T1 in the cholesterol Raman
map with the neutral-lipid-rich red area in the
Nile-blue-stained cryosection. In the latter,
some parallelism between the distribution of
acidic-lipid-rich blue punctate sites and that of
very intense one-pixel-wide spots inside T1 in
the PL/TG Raman map resulted as well.
However, there were also some inconsisten-
cies, the most apparent being the lack of a T2-
like area in the histological counterpart. It
should be kept in mind that uncontrollable
events can affect reliability and reproducibility
of the patters supplied by this high-affinity
staining, depending on heterogeneous dye-to-
substratum affinities and not steady stain-to-
stain competition degrees. The existence of
further consistency between the lipid Raman
maps and that of HA supports the finding that
lipid accumulation closely correlates with
priming of biomineralization, in spite of the
prima facie contradictory very low lipid intensi-
ty just at level of the calcific nodule. Likely, this
conflicting result can be ascribed to a masking
effect exerted by the overwhelming precipita-
tion of HA crystals at the level of this promi-
nently calcified area. Taking into account that
i) PLs/TGs were the sole lipid moiety showing
some intensity inside the calcific nodule area;
and ii) prominent Nile blue staining was
apparent at calcific nodule edges, the concept
supported is that a major role in HA crystal pre-
cipitation is played by PLs, consistent with
reports on ectopic calcification including in
vivo pathological conditions8,9 as well as exper-
imental ones using in vivo11–14 and in vitro15,16
models. The microspectroscopic identification
of cholesterol in mineralizing areas is consis-
tent with neutral lipid accumulation represent-
ing a distinctive feature of CAVS,2,3 in which
oxidized cholesterol might contribute to valve
mineralization.28
To our knowledge, this study provided the
first-time identification of carotenoids in
stenotic valve leaflets, besides revealing their
co-accumulation with the other lipid forms at
valve mineralizing areas. Being carotenoids
transported in the human plasma by LDLs
together with cholesterol,29 it might be
assumed that LDL-cholesterol-carotenoid com-
plexes are phagocytized by lipid-loading
macrophages and AVICs during the early
stages of CAVS. Since Raman microspec-
troscopy already revealed the presence of
carotenoids as well as their co-localization
with lipid deposits in atherosclerotic
plaques,18-20 the concept is supported that CAVS
represents a type of valve atherosclerosis,4,5
with progressive LDL entering and lipid-laden
cell degeneration/death being shared features
in these two types of cardiovascular diseases.
Taking also into account that i) carotenoids
can be revealed very easily because of their
very intense spectral peaks, and ii) Raman
spectra were already obtained in vivo by shin-
ing the laser beam upon artery wall atheroscle-
rotic lesions via miniaturized fiber-optical
probes,30,31 it is worth noting that the in vivo
microspectroscopic identification of
carotenoids might be usefully exploited to
improve the poor capability of a precocious
CAVS diagnosis.
Good consistency between Raman maps and
histological patterns resulted also for collagen
distribution, since mapped areas showing very
low collagen intensity roughly corresponded to
those completely lacking in eosinophilia in the
histological counterpart. Since the same areas
in turn roughly corresponded to those with
very high HA intensity, it is feasible that in
valve mineralizing areas degeneration of colla-
gen fibers may take place, consistent with
inflammation-dependent release of matrix
metalloproteinases by resident AVICs.3
Additional consistency concerned elastin dis-
tribution since both the Raman map and the
Movat-stained para-serial cryosection showed
this protein to be mainly present in the ven-
tricularis layer, consistent with native valve
leaflet structure as well as the fact that this
valve region usually retains its normal features
remaining free from mineralization.2
In conclusion, Raman maps added informa-
tion on the presence and topographical distri-
bution of precipitated calcium, accumulated
lipids including cholesterol/carotenoids, and
altered extracellular matrix components in
CAVS-affected valve leaflets. Moreover, Raman
microspectroscopy was found to represent a
potential technique to investigate in vivo the
alterations anticipating or characterizing this
atherosclerosis-like valve disease.
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Abstract
Decrease in fibroblast-produced collagen
has been proven to be the pivotal cause of skin
aging, but there is no satisfactory drug which
directly increases dermal thickness and col-
lage density. Here we found that a flavonoid
natural product, apigenin, could significantly
increase collagen synthesis. NIH/3T3 and pri-
mary human dermal fibroblasts (HDFs) were
incubated with various concentrations of api-
genin, with dimethyl sulfoxide (DMSO) serv-
ing as the negative control. Real-time reverse-
transcription polymerase chain reaction
(PCR), Western Blot, and Toluidine blue stain-
ing demonstrated that apigenin stimulated
type-I and type-III collagen synthesis of fibrob-
lasts on the mRNA and protein levels.
Meanwhile, apigenin did not induce expres-
sion of alpha smooth muscle actin (α-SMA) in
vitro and in vivo, a fibrotic marker in living tis-
sues. Then the production of collagen was con-
firmed by Masson’s trichrome stain,
Picrosirius red stain and immunohistochem-
istry in mouse models. We also clarified that
this compound induced collagen synthesis by
activating smad2/3 signaling pathway. Taken
together, without obvious influence on fibrob-
lasts’ apoptosis and viability, apigenin could
promote the type-I and type-III collagen synthe-
sis of dermal fibroblasts in vitro and in vivo,
thus suggesting that apigenin may serve as a
potential agent for esthetic and reconstructive
skin rejuvenation.
Introduction
Dermis consists of several structural compo-
nents, and collagen takes the major part. In
addition to glycosaminoglycans and elastin
fibers, dermal matrix in adult skin are com-
posed of type I (80-85%) and type III collagen
(10-15%).1 It is of great importance that colla-
gen plays a main role in the texture and
appearance of skin. Skin aging is inevitably
associated with a disturbance in collagen
metabolism2 (due to the decreased activity of
fibroblasts and their collagen synthesis), as
well as elastin. Increasing the collagen content
of dermis has been regarded as a well-effective
way for anti-aging in skin.
Collagen is a kind of biomacromolecule and
it cannot be absorbed through the stratum
corneum. Recently, some researches demon-
strated that collagen hydrolysate ingestion
might be beneficial to slow chronological skin
aging3 and photoaging4 in rats, and the density
of collagen fibrils increased compared with lac-
talbumin and water controls.5 But the clinical
effect of oral collagen hydrolysate still lacks
convincing evidences. Up to now, injectable
collagen1 or analogous composition6 filling
implants are recognized as the well-accepted
treatment modality for cosmetic purposes.
However, maintaining skin appearance relies
on expansive and complex treatment repeated-
ly because of the short-term duration of exo-
genic injected collagen.
Apigenin (4,5,7-trihydroxyflavone), a
flavone subclass of flavonoid widely distributed
in many herbs, fruits, and vegetables, is a sub-
stantial component of the human diet and has
been shown to possess a variety of biological
characteristics, including anti-oxidative,7 anti-
inflammatory effect,8 tumor growth inhibition9
and promoting neurogenesis.10 It has been
shown that apigenin could enhance wound
healing and tissue repair in diabetic rat skin.11
In the process of wound healing, fibroblasts
secreted collagen and the formation of colla-
gen-rich granulation tissue are vital patho-
physiological mechanisms for wound closure.12
Given this, we wonder what effect would
apigenin have on fibroblasts and whether api-
genin could induce collagen synthesis in nor-
mal human dermal fibroblasts. Consequently,
we examined its effects on collagen synthesis
in normal human dermal fibroblasts in vitro
and tested its function in the skin aging mouse
model induced by D-Galactose. Furthermore,
we investigated the potential mechanism
involved in the positive effects of apigenin on
collagen expression in fibroblasts.
Materials and MethodsCell culture
Primary human dermal fibroblasts were
obtained from adolescent foreskin tissue of ten
people (aged 8-12 years), and none of them
had a history with skin diseases. Skin tissue
was obtained after obtaining informed consent
from the patients, with the approval of the
ethics committee of Shanghai 9th People’s
Hospital and in conformity with the Helsinki
guidelines. NIH/3T3 and human dermal fibrob-
lasts (HDFs) were maintained in DMEM
(Hyclone, Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10% fetal bovine
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serum (Hyclone, Thermo Fisher Scientific),
100 U/mL penicillin, and 100 mg/L strepto-
mycin. Both HDFs and NIH/3T3 were incubated
at 37°C in a humidified atmosphere with 5%
CO2. Primary fibroblasts of passages 6-8 were
used. Toluidine blue (Sigma-Aldrich, St. Louis,
MO, USA) staining was used to assess extra-
cellular matrix synthesis.13Real-time PCR analysis
The total RNA of cells was isolated using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
and subjected to reverse transcription with
Oligo (dT) and M-MLV Reverse Transcriptase
(Thermo Fisher Scientific). Synthesized com-
plementary DNA (cDNA) was analysed with
quantitative real-time PCR using SYBR®
Premix (Takara, Dalian, China) and Roche480
system. Glyceraldehyde 3-phospate dehydroge-
nase (GAPDH) was used as a reference gene.
Primers sequences were as follows: collagen,
type I, alpha 2 (Col1a2; mouse), 5-GGTGAGC-
CTGGTCAAACGG-3  (forward) and 5 - ACTGT-
GTCCTTTCACGCCTTT-3  (reverse); Col1a2
(human), 5 -GGCCCTCAAGGTTTCCAAGG-3
(forward) and 5 -CACCCTGTGGTCCAA-
CAACTC-3  (reverse); collagen, type III, alpha 1
(Col3a1; mouse), 5 - CTGTAACATG-
GAAACTGGGGAAA-3  (forward) and 5 -
CCATAGCTGAACTGAAAACCACC-3  (reverse);
Col3a1 (human), 5 -TTGAAGGAGGATGTTCC-
CATCT-3  (forward) and 5 - ACAGACA-
CATATTTGGCATGGTT-3  (reverse); matrix
metalloproteinases 1 (MMP1; human), 5 -
AAAATTACACGCCAGATTTGCC-3  (forward)
and 5 -GGTGTGACATTACTCCAGAGTTG-3
(reverse); matrix metalloproteinases 2
(MMP2; human), 5 -TACAGGATCATTGGCTA-
CACACC-3  (forward) and 5 -GGTCA-
CATCGCTCCAGACT-3  (reverse); matrix metal-
loproteinases 9 (MMP9; human), 5 -TGTAC-
CGCTATGGTTACACTCG-3  (forward) and 5 -
GGCAGGGACAGTTGCTTCT-3  (reverse); tissue
inhibitor of metalloproteinases1 (TIMP1;
human), 5 -CTTCTGCAATTCCGACCTCGT-3
(forward) and 5 -ACGCTGGTATAAGGTG-
GTCTG-3  (reverse); α-SMA (human), 5 -
AAAAGACAGCTACGTGGGTGA-3  (forward) and
5 -GCCATGTTCTATCGGGTACTTC-3  (reverse).Cell viability assay
For the cell viability assay, HDFs were seed-
ed on 96-well plates (100 mL per well), fol-
lowed by apigenin (cat. no. 42251; Sigma-
Aldrich) or DMSO (Sigma-Aldrich) treatment.
After 3 or 5 days, cell culture medium was
replaced by Thiazolyl Blue Tetrazolium
Bromide (MTT) working solution, followed by
a 4-hour incubation at 37°C in a 5% CO2 incu-
bator. After MTT working solution was
removed and DMSO added, the absorbances at
490 nm were detected.
Flow cytometric analysis
Cell apoptosis was assessed by flow cytome-
try using the Alexa Fluor® 488 Annexin V/Dead
Cell Apoptosis Kit (Invitrogen, Carlsbad, CA,
USA). Following apigenin (5 μmol/L or 1
μmol/L) or dimethyl sulfoxide (DMSO) treat-
ment, harvested cells were suspended in 100
μL Annexin-binding buffer. Then, 5 μL Alexa
Fluor® 488 Annexin V and 1 μL PI working
solution were added and incubated with the
cells for 15 min in the dark. After the incuba-
tion period, 400 μL 1X Annexin-binding buffer
was added and mixed gently. The stained cells
were analysed directly by flow cytometry using
the Cell Quest program (Becton Dickinson, CA,
USA). Data were analysed using FlowJo soft-
ware.Colony formation assay
Anchorage-dependent growth of HDFs were
investigated by monolayer colony formation
assay.14 Cells were cultured in a 6-well plate
(500 per well) and treated with 5 μmol/L or 1
μmol/L apigenin or DMSO. After cultured for
14 days, surviving colonies were stained 5 min
with Gentian Violet (Sigma-Aldrich) after 4%
paraformaldehyde fixation.Immunofluorescence cell staining
Human dermal fibroblasts at a density of
2×103 cells per well were seeded on cover
slides in 24-well plates and incubated
overnight. Cells were fixed with 4%
paraformaldehyde and blocked with 5% goat
serum in PBST (0.1% TritonX-100 in phos-
phate buffered saline) for 1 h. For F-actin
staining, cells were incubated with Alexa Fluor
488 Phalloidin (Cytoskeleton Inc., Denver, CO,
USA; 1:200) for 1 h at room temperature. For
α-SMA staining, cells were incubated with pri-
mary antibodies against α-SMA (Abcam,
Cambridge, UK, 1:200) for 2 h at room temper-
ature, followed by an Alexa Fluor 555-conjugat-
ed secondary antibody. For smad3 staining,
cells were incubated with primary antibodies
against smad3 (Cell Signaling Technology,
Beverly, MA, USA; 1:200) for 2 h at room tem-
perature, followed by an Alexa Fluor 488-conju-
gated secondary antibody. Immunofluore -
scence signals were captured using confocal
microscopy (LSM 510, META Laser Scanning
Microscope; Zeiss, Jena, Germany).Smad2/3 knockdown by siRNA
RNA interference was performed using
smad2/3 siRNA (human) (sc-37238; Santa
Cruz Biotechnology, Dallas, TX, USA), target-
ing human smad2/3 and control siRNA (sc-
37007) as negative control. Transfection for
HDFs was conducted using Lipofectamine
RNAiMAX reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol.
Western blot
Cultured cells were lysed using radioim-
munoprecipitation assay (RIPA) lysis buffer.
Protein concentrations were determined using
a micro bicinchoninic acid (BCA) assay
(Thermo Fisher Scientific). Twenty micro-
grams total protein extract was separated by
8% or 10% sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE) under
reducing conditions and electroblotted onto
polyvinylidene difluoride membranes
(Millipore, Bedford, MA, USA). The membrane
was then blocked and then incubated with pri-
mary antibodies overnight at 4°C.
The primary antibodies used included the
followings: anti-Col1a2, anti-Col3a1, anti-α-
SMA (Abcam; 1:1000), anti-cyclin-dependent
kinase (CDK) family, anti-cyclin D1, anti-
cyclin E1, anti-smads, anti-MAPK family (Cell
Signaling Technology, Beverly, MA, 1:1000),
anti-GAPDH (Sigma-Aldrich; 1:10,000).
Immunoreactive bands were quantitatively
analyzed with ImageJ software.D-galactose-induced skin agingmouse model and animal experiments
Six-week-old female C57BL/6 mice were
purchased from the Shanghai Slac Laboratory
Animal (Slac, Shanghai, China). All animal
studies have been approved by the Animal
Care and Use Committee of Shanghai Jiao
Tong University. All efforts were made to mini-
mize animal suffering.
A total of 18 mice were randomly assigned to
three groups (n=6). Two groups of animals
received daily subcutaneous injection of D-
galactose (D-gal; 1000 mg/kg) for 8 weeks.15
The third group received phosphate buffered
saline (PBS) as a negative control. Two weeks
later, DMSO and apigenin (5 μmol/L) was
delivered by microneedles16 [MTS-Roller
Model: CR2 (0.2 mm)] to the dermis of D-
galactose treated mice once a day for 4 weeks,
respectively. Mice were sacrificed at the end of
treatment, and skin tissue was harvested for
further analyses.Histology and immunohistochemistry
Paraformaldehyde-fixed paraffin-embedded
tissue sections (5 μm) were stained with
hematoxylin and eosin (H&E), Masson’s
trichrome (Trichrome stain LG solution,
HT10316; Sigma-Aldrich) and Picrosirius red
(Fluka, Buchs, Switzerland). For immunohis-
tochemical staining, the sections were detect-
ed with primary antibodies against collagen
I/III (Millipore; 1:1,000) and α-SMA (Abcam;
1:200) overnight at 4°C. After incubation with
the appropriate secondary antibodies, the sec-
tions were developed with diaminobenzidine
and counterstained with hematoxylin.
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Statistical analysis
Statistical differences were calculated using
Friedman’s analysis of variance (ANOVA), with
post-hoc least significant difference (LSD) test
as appropriate. A significant difference among
groups was set at P<0.05.
ResultsApigenin stimulated collagen synthesis but had no effect onmatrix metalloproteinases in vitro
Fibroblasts are the predominant mesenchy-
mal cells in the dermis, and their function is
strongly implicated in dermatology. To study
apigenin’s effect on fibroblasts (Figure 1A),
NIH/3T3 and HDFs were administered with
apigenin at the concentrations of 5 μmol/L. As
shown in Figure 1B, apigenin could potently
increase Toluidine blue staining after api-
genin treatment for 5 days, which mean the
                             Original Paper
Figure 1. Apigenin stimulated collagen synthesis of fibroblasts. A) The molecular structure of apigenin. B) Toluidine blue staining in
NIH/3T3 and HDFs for 5 days. C) Dose-dependent effects of apigenin on mRNA expression of Col1a2 and Col3a1 in NIH/3T3 and
HDFs for 3 days. D) The protein level of Col1a2 and Col3a1 was measured by Western Blot at 5 days after apigenin was applied at
concentrations of 0.1 μmol/L to 10 μmol/L. E) The expression of MMP1, MMP2, MMP9 and TIMP1 were also assessed by real-time
PCR. Data are presented as mean ± SD, n≥3; NS, not significant; *P<0.05; **P< 0.01; ***P<0.001.
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synthesis of extracellular matrix was
increased.13 Further real-time PCR analysis
showed that, in NIH/3T3 and HDFs, apigenin
(0.1 μmol/L - 10 μmol/L) dose-dependently
stimulated endogenous expression of Col1a2
and Col3a1. The most significant changes
were observed when NIH/3T3 and HDFs were
treated with apigenin at the concentration of 5
μmol/L, and the increase of Col3a1 was more
obvious than Col1a2 (Figure 1C). These upreg-
ulation effect of apigenin on collagen expres-
sion were then confirmed by Western blot
analysis. When HDFs were treated with api-
genin for 5 days, the protein level of Col1a2
and Col3a1 were higher than that of cells treat-
ed with DMSO (Figure 1D). In addition, we
next examined the effect of apigenin on
matrix metalloproteinases (MMPs) and
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Figure 2. No obvious cytotoxicity exerted by apigenin on fibroblasts viability, apoptosis, proliferation, cell cycle and activation. A) Cell
viability was examined by MTT assays at 3 or 5 days after apigenin was applied in HDFs. B) Apoptosis was evaluated after treating
HDFs with 5 μmol/L or 1 μmol/L apigenin or DMSO; flow cytometry profile represents Alexa Fluor® 488 Annexin V staining in X
axis and PI in Y axis. C) The effect of apigenin on fibroblasts growth was investigated by monolayer colony formation assay. D) The
expression of cyclin E1, CDK4, cyclin D1, CDK2 and p-CDK2 proteins was analysed using Western blot in HDFs. E-F) The levels of
α-SMA mRNA and protein expression were measured by real-time PCR and Western blot. G) Immunofluorescence cell staining for α-
SMA and F-actin in cultured HDFs after incubation with apigenin or DMSO for 72 h; F-actin is shown by green fluorescence and α-
SMA is shown by red fluorescence; nucleus (blue) was stained with DAPI; scale bar: 50 μm. Data are presented as mean ± SD, n≥3;
NS, not significant; **P<0.01; ***P<0.001.
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TIMP1, well-known proteases that degrade col-
lagen proteins. The expression of MMP1,
MMP2, MMP9, and their inhibitor TIMP1 were
unchanged (Figure 1E).Apigenin did not effect fibroblastsviability and activity
Afterwards, we studied the effect of api-
genin on fibroblasts viability, apoptosis, prolif-
eration and activation. In vitro, MTT assays
showed that the viability of HDFs was similar
with those incubated with DMSO, when incu-
bated with apigenin (1 to 10 μmol/L) for 3 or 5
days, respectively (Figure 2A). In addition, no
significant differences in percentages of apop-
totic cells was observed after the exposure of
fibroblasts to apigenin (Figure 2B). To investi-
gate the effects of apigenin on proliferation
and cell cycle, colony formation assay and
Western Blot analysis of cell cycle related pro-
teins were performed. Colony forming ability
of HDFs was similar in apigenin-treated group
to DMSO-treated group (Figure 2C). The
expression levels of cell cycle associated pro-
teins remained unchanged between apigenin
and DMSO treated groups (Figure 2D). These
results suggested that apigenin had no obvi-
ous cytotoxicity on fibroblasts’ viability, apop-
tosis and proliferation.
Fibroblast overactivation leads to pathologi-
cal collagen deposition or scar formation.17
Myofibroblasts, known as activated fibroblasts,
are marked by α-SMA expression. To deter-
mine the effects of apigenin on fibroblasts’
activation, we evaluated the levels of α-SMA
mRNA and protein expression (Figure 2 E,F)
in cultured HDFs treated with apigenin. We
found that α-SMA mRNA expression had no
obvious change in apigenin-treated cells com-
pared with DMSO-treated cells. We also
showed that apigenin did not affect α-SMA
expression in vitro by immunofluorescence
staining (Figure 2G). These findings suggest-
ed that apigenin did not cause fibroblasts to
overactivate into myofibroblasts while colla-
gen synthesis was increasing.Induction of collagen synthesis wasmediated by smad2/3 activation
To further explore the underlying mecha-
nism of how apigenin activated type-I and
type-III collagen gene expression, transform-
ing growth factor beta 1 (TGF-β1) and mito-
gen-activated protein kinase (MAPK) signal-
ing pathway were analysed. TGF-β1 is a proto-
typic fibrogenic cytokine, enhancing extracel-
lular matrix gene expression. Previous studies
proved that Col1a2 and Col3a1 were direct
TGF-β1/smad3 targets in human dermal
fibroblasts.18 As shown in Figure 3A, when
HDFs were treated for 12 h, apigenin (1
μmol/L or 5 μmol/L) markedly increased the
expression of phosphorylated smad2 and
smad3 in a dose-dependent manner, whereas
total smad2, smad3 and smad4 did not obvi-
ously alter. It also showed that apigenin had
sustained effect on promoting phosphorylation
of smad2 and smad3 after a 3-day treatment
(Figure 3B). Yoon et al.19 revealed that MAPK
pathway was involved with peptide-induced
collagen synthesis of fibroblasts. However,
when fibroblasts were treated with apigenin
for 12 h, the expression of total and phospho-
rylated JNK, ERK and p38 protein remained
unchanged, compared with DMSO (Figure
3C). Immunofluorescence experiments de -
monstrated that after treatment with apigenin
for 12 h, smad3 protein (labeled by green) was
significantly increased and mostly translocat-
ed into the nucleus (labeled by blue) (Figure
3D). By contrast, in the DMSO groups, smad3
were retained in the cytoplasm. Once targeted
knockdown smad2/3 by specific siRNA, the up-
regulation effect of apigenin on the expres-
sion of collagen type-I and type-III protein was
obviously reduced (Figure 3E), which con-
firmed that smad2/3 is required for the trans-
duction of apigenin effect on collagen expres-
sions.Apigenin stimulated collagen syn-thesis in the D-galactose-inducedskin aging mouse model
The in vivo effects of apigenin on collagen
synthesis was investigated in the D-galactose-
induced skin aging mouse model. The collagen
expression was showed by H&E, Masson’s
trichrome stain, Picrosirius red stain and
immunohistochemistry. Histology showed sig-
nificant changes in dermal thickness and den-
sity in samples obtained from D-gal-treated
mice compared with PBS control group
(Figure 4 A-D). After 1 month of apigenin
administration at the concentration of 5
μmol/L, the mice exhibited obviously
increased dermal thickness and collagen den-
sity compared with DMSO-treated mice
(Figure 4 A-D). Magnified images showed that
dermis in the apigenin-treated group exhibit-
ed compact and clearly evident staining,
whereas collagens were loosely distributed in
DMSO-treated dermis of the aging skin model
(Figure 4 A-D), in both Masson’s trichrome
stain, Picrosirius red stain and immunohisto-
chemistry examinations. Dermal collagen
could be subdivided into type I and type III col-
lagen after Picrosirius red staining under
polarized light. As shown in Figure 4F, api-
genin could significantly increase both colla-
gen type I and type III density in the dermis of
the skin aging mouse model. Quantitative data
of dermal thickness and collagen density
showed that mice subcutaneously injected
with D-gal showed thinner skin and less colla-
gen compared to control mice and apigenin-
treated mice demonstrated significantly thick-
er and compact dermis (Figure 4 E,F). The in
vivo study also demonstrates that apigenin
does not show any effect on activation of
fibroblasts (Figure 4G).
Discussion
Dermal atrophy is the major causes of aging
appearance.20 In vivo and in vitro studies show
that decline in the production of collagen in
aging fibroblasts is mainly responsible for
decreasing in dermal thickness seen in extrin-
sically aging skin, which reveals dermal atro-
phy, fragmentation, and irregular collagen
bundles.21 Since the ‘70s, animal and human
derived collagens have been studied for soft
tissue augmentation.22 Injectable filling
implants are now widely used for cosmetic pur-
poses. However, exogenic injectable collagen
often presented various complications such as
allergy, ecchymosis, local necrosis and infec-
tions of bacteria or virus. Scientists have tried
for decades to find other alternative to stimu-
late endogenous collagen synthesis. There are
several anti-oxidants, such as vitamins C and
E, co-enzyme Q10 and retinoids used for treat-
ing UV-induced skin aging and wrinkles.23, 24
However, only few compounds are able to
induce type I collagen synthesis25-27 and none
of them can stimulate both type I and type III
collagen synthesis according to the record in
literatures.
Apigenin, a plant flavone, has gained con-
siderable attention due to its health benefits,
chemopreventive properties and wide distribu-
tion in the plant kingdom.28 Many studies have
demonstrated that apigenin possesses a wide
range of biological activities to the skin. It has
been reported that apigenin can stimulate
nucleotide excision repair genes to protect
skin keratinocytes29 against UVB-induced skin
inflammation.30 Dietary apigenin attenuates
the development of atopic dermatitis-like skin
lesions in atopic dermatitis model.31 Apigenin
could also effectively reduce the incidence and
size of skin tumors caused by ultraviolet B
(UVB) exposure through the enhancement of
UVB-induced apoptosis.32 In this study, we
investigated the effect of apigenin on dermal
fibroblasts’ function.
At first, we found apigenin could increase
the mRNA expression of Col1a2 and Col3a1 in
NIH/3T3 and HDFs. With extracellular matrix
staining and Western Blot analysis, the stimu-
lative effect of collagen on protein level was
more significant. Although as reported in the
literature, basal levels of Col1a1 and α-SMA
mRNAs were reduced in fibroblasts treated
with high concentration of apigenin (20
μmol/L),33 our research confirmed that api-
genin of 25 μmol/L showed obvious cytotoxici-
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Figure 3. Apigenin-mediated collagen synthesis increase via smad2/3 signaling pathway. A,B) Western blot analysis and quantification
of phosphorylated and total smad2, smad3 and total smad4 in HDFs with or without apigenin stimulation for 12 h or 3 days. C)
Western Blot analysis of JNK, ERK and p38 in HDFs with or without apigenin stimulation for 12 h. D) Immunofluorescence experi-
ments: smad3 was labeled as green; nucleus (blue) was stained with DAPI; scale bar: 50 μm. E) Western blot showed the expression of
Col1a2 and Col3a1 in HDFs when cells were treated with DMSO, apigenin or apigenin with specific siRNA of smad2/3. Data are pre-
sented as mean ± SD, n≥3; NS, not significant; *P<0.05; **P<0.01; ***P<0.001.
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Figure 4. Apigenin increased dermal thickness and collagen density in the D-galactose-induced skin aging mouse model. A-D) H&E,
Masson’s trichrome, Picrosirius red and immunohistochemistry stained dermis of control mice and D-gal-treated mice respectively
received apigenin and DMSO; scale bars: 100 μm; zoom scale bars: 20 μm. E) Quantification of dermal thickness. F) Picrosirius red
staining under polarized light and quantification of type I and type III collagen density; collagen type I is shown as red fibers and col-
lagen type III is shown as green fibers; scale bars: 100 μm. G) Immunohistochemistry staining of α-SMA of control mice and D-gal-
treated mice respectively received apigenin and DMSO; scale bars: 100 μm; zoom scale bars: 20 μm. Data are presented as mean ± SD,
n=6/6/6; *P<0.05; **P<0.01; ***P<0.001.
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ty in fibroblasts. We believed that the attenuat-
ing effect of high concentration of apigenin on
phenotypic transitions in the analyzed cell pop-
ulations were not independent of its cytotoxic
activity. We detected the markers related to
extracellular matrix degradation and found
that apigenin had no effect on the balance of
MMPs/TIMPs. 
We further observed that apigenin directly
activated smad2/3-dependent signaling path-
way. This is not surprising since this flavonoid
displays considerable muti-effect. It targets a
number of secondary messengers, including
those potentially involved in TGF-β1 signaling
pathway, such as NF-kB,34 MAPK/ERK,35
FAK,36,37 PKC38 and PI3K-Akt39 in a cell context-
dependent manner. We observed that apigenin
markedly increased the expression of phos-
phorylated smad2 and smad3 protein, while
total smad2, smad3 and smad4 protein all
remained unaltered. So, a more meticulous
network may connect TGF-β1 signaling path-
way and the abovementioned secondary mes-
sengers.
A previous study showed the accelerated
aging effect of D-gal injection on mouse skin,
as well as changes in dermal thickness and col-
lagen content.15 In order to confirm the effect
of apigenin on collagen synthesis in vivo, the
D-galactose-induced skin aging mouse model
was established. Our data indicated that skin
aging mice treated with apigenin showed
markedly increasing dermal thickness and col-
lagen expression, compared with DMSO-treat-
ed mice. Hou et al.40 reported that topical api-
genin improved epidermal permeability barrier
function by stimulating epidermal differentia-
tion, lipid synthesis and secretion, as well as
cutaneous antimicrobial peptide production,
and our result showed that dermal injection of
apigenin significantly increased dermal thick-
ness and density. So we could conclude that
apigenin caused different biological functions
with two forms of drug administration by act-
ing on epidermis or derma, which might indi-
cate the importance of choosing suitable
administration methods to different skin dis-
eases, even for the same drug.
Our study demonstrates that apigenin could
induce both type I and type III collagen synthe-
sis of fibroblasts in vitro and could increase
dermal thickness and collagen deposition in
the dermis of mice. This compound is a poten-
tial target for drug design and development for
esthetic and reconstructive purpose. 
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